Doxorubicin (generic), Adriamycin, Doxil News

This study evaluated the efficacy and safety of S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in patients with HER2-negative, stage II-III breast cancer.

Merrimack Pharmaceuticals, Inc. today announced that Phase 1 data evaluating safety of the novel agent MM-302 in patients with advanced HER2-positive breast cancer will be presented at the 2013 San Antonio Breast Cancer Symposium , December 10-14, 2013 in San Antonio, Texas.

In this study, a co-delivery system of plasmid encoding human tumor necrosis factor-related apoptosis-inducing ligand and doxorubicin has been simply constructed in two steps."

Puma Biotechnology, Inc. , a development stage biopharmaceutical company, today announced top line results from the Phase II clinical trial of Puma's investigational drug PB272 for the neoadjuvant treatment of breast cancer .

Summary: A 26-year-old male presented with complaints of pain and swelling in the right lower thigh lasting a month.

Merrimack Pharmaceuticals Inc. 's MM-121 Demonstrates Positive Signal In Two Phase 2 Breast Cancer Studies; Stock Up +10.41% On Tuesday At 9:56AM ET Merrimack Pharmaceuticals' MM-121 Demonstrates Positive Signal in Two Phase 2 ER/PR+ Breast Cancer Studies CAMBRIDGE, Mass., Nov. 26, 2013 -- Merrimack Pharmaceuticals, Inc. today announced the results ... (more)

The tumor suppressor p53 is a sequence-specific transcription factor that regulates an extensive network of coding genes, long non-coding RNAs and microRNAs, that establish intricate gene regulatory circuits influencing many cellular responses beyond the prototypical control of cell cycle, apoptosis and DNA repair.

The development of a probe to measure the body's immune function could lead to more accurate, individualized doses for cancer patients prescribed nanoparticle-based drugs, according to research conducted at the University of North Carolina.

Topotarget announces the final results from the first stage of the phase II part of the phase I/II clinical trial of belinostat in combination with doxorubicin in patients The phase I dose escalation part of this study showed that belinostat at a recommended dose of 1000 mg/m2 days 1-5 in combination with 75 mg/m2 doxorubicin on day 5 in a ... (more)

Just over a month ago, I wrote an article to educate investors about a company called CytRx that has a drug named aldoxorubicin.

The Board of Directors of MolMed S.p.A., chaired by Prof. Claudio Bordignon, today reviewed and approved the interim financial report at 30 September 2013.

The Board of Directors of MolMed S.p.A., chaired by Prof. Claudio Bordignon, today reviewed and approved the interim financial report at 30 September 2013.

Ionic complexation was used to enhance the loading efficiency and release characteristics of water soluble form of Dox."